Tanezumab, identified by the research designation 880266-57-9, represents a targeted antibody compound demonstrating significant potential in treating debilitating osteoarthritis pain. This humanized antibody uniquely targets sensory growth element , inhibiting its effect and thereby lessening inflammation within affected areas . The clinical data surrounding 880266-57-9 highlights its power to offer noticeable suffering alleviation while perhaps avoiding the dependence for traditional analgesics. Further studies are actively underway to completely determine its sustained security and effectiveness .
Grasping Tanezumab's Function in Ache Alleviation: An Immune Protein Perspective
Tanezumab, a novel treatment approach, offers a unique pathway in persistent pain control. As a humanized antibody, it specifically targets and blocks nerve development factor (NGF), a key molecule participating in nerve ache signaling. Unlike conventional opioid medications, tanezumab’s antibody mechanism allows for a greater targeted action, arguably reducing the likelihood of some frequent side reactions connected with systemic pain relief. However, its immunological nature necessitates a detailed assessment of potential body's reactions and long-term effects when administered within a comprehensive pain management plan.
Tanezumab Solution (880266-57-9): Purity , Quality & Functions
The Tanezumab Compound with the identifier 880266-57-9 is a vital component in various research applications, particularly concerning chronic inflammation treatment development. Achieving a high level of purity is paramount; therefore, rigorous assessment protocols are employed to guarantee its suitability for intended use. Our creation procedure focuses on maximizing refinement, employing sophisticated filtration techniques to remove contaminants . Typical specifications include a >95% purity level as determined by Liquid Chromatography and comprehensive examination for biochemical integrity. The primary uses revolve around its role as a experimental agent for investigating processes of cartilage damage and developing novel therapeutic interventions .
- Research Investigations
- Medical Development
- Pathway Studies
A Science Of Tanezumab: Examining the 880266-57-9 Protein
Tanezumab, identified with the chemical identifier 880266-57-9, represents a innovative biological antibody targeting sensory growth factor receptor (NGF). Tanezumab protein Its mode of action revolves upon specifically binding to NGF, consequently reducing its function and following signal transduction. Scientists have revealed that this biologic molecule offers opportunity for alleviating severe discomfort, particularly associated with conditions like osteoarthritis and lower back pain. Additional research are underway to completely characterize its impact and well-being characteristics.
Latest Developments in The Research: Examining the Its Reagent
Current studies surrounding tanezumab, a novel therapeutic compound, are increasingly directed on characterizing the role of the particular reagent, 880266-57-9. This discovery and thorough evaluation of the biological entity seems necessary for improving the drug's performance and minimizing anticipated adverse reactions. Early results indicate that 880266-57-9 contributes a key function in the therapy's mode of operation. More investigations will be needed to entirely elucidate its effect.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}